PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8181099

[Bimorphic malignant lymphoma].

F Fakan·A Skálová·M Michal
View original source ↗Export metadata ↓

Abstract

Two distinct morphological types of malignant lymphoma in the same patient occur mostly due to transformation of a low-grade lymphoma to high-grade lymphoma. When two morphologically different structures are found at different sites they represent discordant lymphoma. Composite lymphoma, on the other hand, shows two histologic subtypes involving the same location. Bimorphic morphology of malignant lymphoma is of therapeutic and prognostic significance.

Explore related subjects

Hodgkin DiseaseHumansLymphoma, Non-HodgkinNeoplasms, Multiple PrimaryEnglish AbstractJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

F Fakan, A Skálová, M Michal. 1994. [Bimorphic malignant lymphoma].. https://pubmed.ncbi.nlm.nih.gov/8181099/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications.

The transcription factor NF-kappaB is a tightly regulated positive mediator of T- and B-cell development, proliferation, and survival. The controlled activity of NF-kappaB is required for the coordination of physiologic immune responses. However, constitutive NF-kappaB activation can promote continuous lymphocyte proliferation and survival and has recently been recognized as a critical pathogenetic factor in lymphoma. Various molecular events lead to deregulation of NF-kappaB signaling in Hodgkin disease and a variety of T- and B-cell non-Hodgkin lymphomas either up-stream or downstream of the central IkappaB kinase. These alterations are prerequisites for lymphoma cell cycling and blockage of apoptosis. This review provides an overview of the NF-kappaB pathway and discusses the mechanisms of NF-kappaB deregulation in distinct lymphoma entities with defined aberrant pathways: Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), mucosa-associated lymphoid tissue (MALT) lymphoma, primary effusion lymphoma (PEL), and adult T-cell lymphoma/leukemia (ATL). In addition, we summarize recent data that validates the NF-kappaB signaling pathway as an attractive therapeutic target in T- and B-cell malignancies.

Hodgkin Disease↗